NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Natl Compr Canc Netw

Title: Journal of the National Comprehensive Cancer Network : JNCCN

Publisher: Harborside Press, LLC

ISSN (Electronic): 1540-1413

ISSN (Print): 1540-1405

Publication date (Electronic): June 01 2019

Volume: 17

Issue: 6

Affiliations

[1 ] Memorial Sloan Kettering Cancer Center.

[2 ] Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

[3 ] Massachusetts General Hospital Cancer Center.

[4 ] Stanford Cancer Institute.

[5 ] Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

[6 ] Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

[7 ] University of Wisconsin Carbone Cancer Center.

[8 ] Moffitt Cancer Center.

[9 ] The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

[10 ] The University of Texas MD Anderson Cancer Center.

[11 ] Huntsman Cancer Institute at the University of Utah.

[12 ] Mayo Clinic Cancer Center.

[13 ] Roswell Park Comprehensive Cancer Center.

[14 ] University of Michigan Rogel Cancer Center.

[15 ] Duke Cancer Institute.

[16 ] Fox Chase Cancer Center.

[17 ] Consultant.

[18 ] Dana-Farber/Brigham and Women's Cancer Center.

[19 ] O'Neal Comprehensive Cancer Center at UAB.

[20 ] City of Hope National Medical Center.

[21 ] University of Colorado Cancer Center.

[22 ] Vanderbilt-Ingram Cancer Center.

[23 ] UC San Diego Moores Cancer Center.

[24 ] Yale Cancer Center/Smilow Cancer Hospital.

[25 ] University of Washington/Seattle Cancer Care Alliance.

[26 ] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

[27 ] Fred & Pamela Buffett Cancer Center; and.

[28 ] National Comprehensive Cancer Network.

Article

Publisher Item ID: jnccnINSBCELL1706

DOI: 10.6004/jnccn.2019.0029

PubMed ID: 31200358

SO-VID: b8a17e18-9391-45c0-93ed-4226e6416abd

History

Data availability:

Comments

Comment on this article

scite_

Cited by 68

See all cited by